OTC · Consumer staples

Goldenwell Biotech, Inc. (GWLL)

Goldenwell Biotech, Inc. brought in $55 of revenue over the twelve months to June 30, 2026. It posted a net loss of $282.1K. At June 30, 2026 it held $11.1K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Watch GWLL in 60 seconds

Price

$0.69

0.00% on the day · September 25, 2026

52-week range $0.20 to $10.00

Market cap

$68.3M

Revenue (last 12 months)

$55

Net margin

-512,940.0%

What Goldenwell Biotech, Inc. does

Goldenwell Biotech, Inc. is registered with the SEC under industry code SIC 2000 (Food and Kindred Products). Its shares trade on OTC under the ticker GWLL.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$55	-$113.3K	-$296.5K	$0.00	n/a
2024	$139	-$123.1K	-$131.5K	$0.00	n/a
2023	$2.3K	-$115.8K	-$117.4K	$0.00	n/a
2022	$47.8K	-$985.1K	-$985.1K	n/a	n/a
2021	$16K	-$118.3K	-$117K	$0.00	n/a
2020	$0	n/a	-$6.3K	$0.00	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around December 7, 2026.

Estimated from its filing rhythm: 52 weeks after its report of December 8, 2025. Not a date the company has announced. See the report calendar

Where GWLL ranks in Consumer staples

Revenue$55

#154 of 154 in Consumer staples · Bottom 1%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Consumer staples

Latest SEC filings

What Goldenwell Biotech, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 14, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS was $0.00.
July 1, 2026
Quarterly report 10-Q · period to March 31, 2026Diluted EPS $0.00 versus $0.00.
July 1, 2026
Annual report 10-K · period to December 31, 2025Revenue fell 60% to $55 versus the prior year; diluted EPS $0.00 versus $0.00.
June 29, 2026
Quarterly report (amended) 10-Q/A · period to September 30, 2025Net loss of $27.9K.
June 26, 2026
Quarterly report (amended) 10-Q/A · period to June 30, 2025Net loss of $30.3K.
June 26, 2026
Quarterly report (amended) 10-Q/A · period to March 31, 2025Diluted EPS was $0.00.
May 27, 2026
Past results no longer reliable 8-K
May 12, 2026
Late quarterly report notice NT 10-Q
March 31, 2026
Late annual report notice NT 10-K
December 8, 2025
Quarterly report 10-Q · period to September 30, 2025Net loss of $27.9K.

Recent insider filings (Forms 3, 4 and 144): 4, the latest on August 22, 2023. Insider transactions on SEC

All filings on SEC EDGAR

Questions about GWLL

What does Goldenwell Biotech, Inc. do?

Goldenwell Biotech, Inc. is registered with the SEC under industry code SIC 2000 (Food and Kindred Products). Its shares trade on OTC under the ticker GWLL.

Is Goldenwell Biotech, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $282.1K on revenue of $55.

How much revenue does Goldenwell Biotech, Inc. make?

Over the twelve months to June 30, 2026 Goldenwell Biotech, Inc. reported revenue of $55.

When did Goldenwell Biotech, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.

Similar companies

MDLZ

Mondelez International, Inc.

Bellring Brands, Inc.

Compare GWLL with

Compare GWLL with any company

Follow GWLL

Get an email when Goldenwell Biotech, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow GWLL: get an email when it files

Where the numbers come from

Financial figures are the values Goldenwell Biotech, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.